New Pharmacotherapeutic Approaches for Chronic Obstructive Pulmonary Disease.

Abstract

The last 5 years have seen a proliferation of data about the best way to treat chronic obstructive pulmonary disease (COPD). New long-acting inhaled β-agonist and antimuscarinic drugs have been developed as a once-daily inhaled corticosteroid. Studies have tested whether these agents are safe and effective alone or in combination. Alternative strategies to treatment including phosphodiesterase-4 inhibition and long-term antibiotic treatment have become reasonable alternatives to more established approaches, at least in terms of preventing COPD exacerbations. New data are beginning to define which patients benefit from which treatments and this will help us develop more appropriate treatment regimes. These topics are considered in this review which provides an overview of the latest data and some direction as to how these findings can be applied in practice.

• Authors: Peter Calverley, Ben Vlies
• Journal: Seminars in respiratory and critical care medicine (Semin Respir Crit Care Med) Vol. 36 Issue 4 Pg. 523-42 (Aug 2015) ISSN: 1098-9048 [Electronic] United States
• PMID: 26238639 (Publication Type: Journal Article, Review)
• Copyright: Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Chemical References

• Adrenergic beta-Agonists
• Anti-Bacterial Agents
• Glucocorticoids
• Phosphodiesterase 4 Inhibitors

Topics

• Adrenergic beta-Agonists (pharmacology)
• Anti-Bacterial Agents (pharmacology)
• Drug Therapy, Combination (methods, trends)
• Glucocorticoids (pharmacology)
• Humans
• Medication Therapy Management (trends)
• Phosphodiesterase 4 Inhibitors (pharmacology)
• Pulmonary Disease, Chronic Obstructive (drug therapy)
• Treatment Outcome